Equity Field Notes from temporal sources

[DanWebzster]

IOVA is the old LBIO

Tumor Infiltrating Lymphocytes ( TILs ) is the platform upon which its deep pipeline is based.

TILs are isolated from a patient's tumor following resection and expanded in vitro away from the cancer's immune suppressing effects.

IOVA has 10 Ph2 programs and 2 Ph1 programs.

Its lead program received Orphan Drug designation for the treatment of Cervical Cancer

The rise of neoantigens may render this platform relatively useless.